including the direct thrombin-inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. A trial fibrill ation (AF) , the most commo n cardiac a rr hy th mia, has become a maj or public health problem. In the United SL ates , the prevalence of AF was estimated at 2.7 to 6.1 million in 2010, and it is expec ted La lise to between 5.6 and 12 million by 2050.
1
The arrh ythmia is associated with impaired qua lity of life and increased morbidity and mort ality 1,1 Stroke remains the most devastating consequence of AF.
The clinical man agement of pati ents with AF typica lly tar gets LwO m ain goals: prevention of s tro ke o r th romboembol ism and co nt rol of sy m p to ms . This articl e add resses th e evo lving pharmacologic and nonpha rma colo gi c s tra teg ies in s tro ke prev ention in nonvalvular AF; reviews clinical trials evalua ting medical and procedural s tra tegies, including the novel oral anticoagul ants a nd left atrial appendage (LAA) exclus io n d evic es; an d assesses th e impact of th ese n ovel strategies on clin ical practice.
RISK OF STROKE AND THROMBOEMBOLISM IN NONVALVULAR AF
Stro ke occ u rre nce from AF is primaril y ca use d by th rombi form ati on in the left a tr iu m , most co mmo n ly in th e LAA. It is important to recogn ize that th e cardiovascular risk fact ors for AF are also risk factors for atheroernb olism ; therefore, speci fic risk factor man age-DECEMBER 2015 • VOLUME 82 • SUPPLEMENT 2 • CLEVELAND CLINIC JOURNAL OF MEDICINE • S11 ment is as import ant as an ticoagulation wh en add ressing stroke risk.
The in cidence of all-c ause s tro ke in pati ents with AF is 5%, and it is beli eved th at AF ca uses ap prox imately 15% of all s trokes in th e Un ite d States .' Th is risk ap pe a rs to be more s ignifican t in older pati ents wh o are more vuln er able to ischemi c strokes . Estimates are that AF indep en dently in creases th e risk of stroke by fivefold through out all ages , with a steep increase in percentage of stro kes a ttribu ted to AF from 1.5% at ages 50 to 59 to 23.5% a t ages 80 to 89 .
1 Importantly, th e clinical course of isch emi c stro ke associated with AF is oft en more seve re th an for stro kes of other causes.' furth er emphasizing the need fo r stro ke pr evention .
Assessment of stroke risk/thromboembolism
Multiple risk es tima tio n scores have been d evel oped based on epidemiologic data. Unt il recently, th e CHADS 1 score" was the most com mo nly used , but it has been superseded by th e CHA 1 DS 2-VASc sco re.' The poin t system for this sco ring sys tem is shown in Tabl e 1. In co ntrast with CHADS 1 , this updated sys tem assigns 2 points for age over 75 years and accoun ts for stroke risk in th e relatively younge r group of pat ien ts (age 65-75) and in females, neither of wh om were included in CHADS 1 . The CHA 1 DS 2 -VASc score rang es betw een 0 and 9 with a respec tive es tima ted stro ke risk o f 0 to 15.2% p er year. No te that for females who are you nge r th an 65 yea rs, no points are given for sex . The major advantage of the CHA1DS1-VASc sc ore over th e CHADS 2 score is that it is mor e accurate for low er-risk ca tegories. It has been ad opted in most of the recent gu ide lines tha t add ress stroke risk in AF In clinical practic e, practiti oners use these scores to define three primary stroke risk categories: low, int ermediate, or high. In our practice, we use a 2% per year cut -off to identify high-ri sk pati ent s in wh om th e risk of stro ke significan tly outweighs the risk of bleeding on anticoagulants. In general, patien ts with a CHA 1 DS 2 -VASc score equal to or greater than 2 have a greater than 2% stroke risk per year and ar e m ost likely to ben efit from a ntithromb otic therapi es.
In male pat ien ts with a CHA,DS,-VASc sco re of 0 and in most patients with a sco re of 1, t he stro ke risk is less than 1% per year. These pati ents are not likely to derive benefit from anticoagul ant th erap y. They are usu ally approached on a case-by-case basis with careful assessment of bleeding risk and discussion of risks and benefits of anticoagulant strategies.
Assessment of bleeding risk
Any ge ne ra l ap proac h to thromb oemboli sm risk assess me n t in pati ents with AF sho uld include an ana lysis th at weigh s the benefits of anticoagul ant th er api es agains t th e risks of bleeding. Alth ou gh no precise too ls exist to predict ble eding risk , the HAS-BLED sco re is increasingly used ." This score assigns 1 point to eac h of the following:
• systolic blood pressure greater than 160 mmHg • abnor mal renal function • abno rmal liver fun ction • age older than 65
• prior cerebrovascu lar event • prior bleedin g • hi story of labile inte rna tio na l normali zed ra tios (INR) • alcoho l intake (>8 U/weck) • drug use, especially antiplatelei agent s or non steroidal ant i-inflamma tory drugs (NSAIDs).
In genera l, a HAS-BLED score of 3 or greater indi cates inc rease d I -year risk of int racranial bleed , bl eed ing requiring hospitalizat ion, drop in hem oglob in of at least 2 gldL, or need for transfusion .
O ne pr oblem with the bl eed in g risk sco res is th at th ey wer e d er ived from st ud ies that included bl eedin g eve n ts of differing se ver ity. Mos t bl eeding eve n ts do not lead to death or se vere di sability with th e exce p tio n of intracranial bleeding, whi ch is, th e refor e, th e prim ar y concern wh en assessing bl eeding risk.
Th e estimated bleeding risk with anti coagulant therapy ranges from 0.2 % to 0.4 % per year but co uld be m uc h hi gh er in patients with prior seve re bl eedin g, in tracra n ia l h em orrha ge , thrombo cytopen ia , co ag ulop athi es , recent surge ry, or o ngo ing bl eed ing , ao rtic d issec tio n, mali gn ant hyp erten si on , and in those receiv ing a co m bina tio n of an tico ag ulan t and an tiplarelet age nts .
MEDICAL THERAPIES TO PREVENT STROKE AND THROMBOEMBOLISM IN AF
In ge nera l, anticoagulation reduces th e risk of isch emi c s tro ke a nd thro mboembolic even ts by app roxi mately tw o-thirds , regardl ess of baseline risk. An ticoagula n t o p tio ns h ave in creased su bs ta n tia lly in th e past few years wi th th e in troduction of no vel o ra l a n ticoagulan ts, including th e direct thrombin -inhibi to r clabi gatran and th e factor Xa inhibi tors rivaroxaban , apixaban , and edo xaban. Although warfarin is one of the most efficacious drugs to prevent stroke in AF, it has several key limitations. The most important is the need for dose adjustment to keep the INR in a narrow window (2.0 to 3.0) in which net clinical benefit is achieved without increased bleeding risk. The need for continuous monitoring is an inconvenience to patients and often leads to drug discontinuation and nonadherence. A meta-analysis found that patients are only in the therapeutic INR about half of the time. " Importantly, the time spent in therapeutic INR range correlates Significantly with the reduction in stroke risk.!" Furthermore, patients who spend less than 40% of the time in the therapeutic INR range are at a higher stroke risk than those not raking warfarin. 10 Another limitation with the medication is the dietary restriction on intake of vitamin K-rich green vegetables, which are emphasized as healthy food choices especially in patients with heart disease. Higher warfarin doses are required in patients who consume greens and salads. It is important that patients be consistent in their intake of vitamin K-rich foods to avoid labile INRs, a difficult task for most patients.
Finally, there are several drugs that might interact with warfarin and potentially interfere with its safety or effi- Aspirin monotherapy or in combination with other agents Aspirin monotherapy or aspirin plus clopidogrel both increase the risk of bleeding without appreciable benefit, and , as such, th eir use for stroke prevention in patients with AF is not well supported. The combination of aspirin plus low-dose warfarin was assessed in the SPAF-III trial!' that randomized AF patients at stroke risk to either aspirin plus low-dose warfarin or to dose-adjusted warfarin to target a therapeutic INR. In this trial, patients on aspirin plus low-dose warfarin had significantly higher morbidity and mortality than patients who took adjusted-dose warfarin alone. Thus, the combination of low-d ose warfarin plus aspirin should not be used for stroke prevention in AE In contras t, the combination of aspirin plus full anticoagulation with warfarin ha s not been well studied. Limited post-hoc data from th e SPORTIF trials suggest, however, that this combination does not reduce the risk of stroke or thromboembolism more than warfarin alone.' ?
Novel oral anticoagulants
Dabigatran. The value of dabigatran for prevention of stroke or thromboembolism in AF wa s tested in the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) .' :' In thi s trial, 18 ,113 patients with AF at high risk for stroke were randomized to dabigatran 010 mg or 150 mg twice daily) or adjusted-dose warfarin (INR target 2.0-3.0). By intention-to-treat analysis, dabigatran 150 mg was superior to warfarin for stroke prevention. Importantly, the risk of intracranial or lifethreatening bleeding was Significantly lower for both dabigatran do ses compared with warfarin. Of note, gastrointestinal bleeding was more common with dabigatran 150 mg than warfarin; rates were similar for dabigatran 110 mg versus warfarin,
Rivaroxaban. This Iactor-Xa inhibitor was assessed in
ROCKET-AF (Rivaroxaban Once-daily oral direct factor Xa inhibition-Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation).!" In this trial , 14,264 patients with AF and at risk SUPPLEMENT 
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for stro ke were randomi zed to rivaroxaban (20 mg once daily) or warfarin (INR target 2.5) . In the wa rfarin ann, INR was in the therapeutic range only 55% of the time . Resul ts showe d rivaroxaban was noninferior, but not superior, to warfarin for the prevention of stro ke or system ic thromboemb olism , the primary end points . From a safety standpoi nt , the overall bleedin g rates were similar in the treatm ent arms with less life-thr eatenin g (fatal or intr acranial) hemorrha ge events with rivaroxaban.
Apixaban. This factor-Xa inhibitor was tested for stroke prevention in AF in two separate clinical trials.P:" In the AVERROES trial (Ap ixaban Versus Acetylsalicylic Acid to Prev ent Strokes), 15 5, 599 patie n ts w ith AF d eem ed "unsuitabl e" for warfarin were randomized to apixaba n (5 mg twice daily) or aspirin (8 1-324 mg daily). The trial was terminat ed early du e to supe riority of apixaba n in achieving the primary end point : occurre nce of stro ke or systemic embolism . Importantly, the risk of major bleeding appeared to be similar with apixaban versus aspirin. The ARISTOT LE (Apixaba n for Redu ction in Stro ke and Other Thromboembo lic Even ts in Atrial Fibrillation) trial '" randomi zed 18,20 1 patients with AF and at least one additio na l risk facto r for stro ke to eithe r ap ixaba n 5 mg or warfarin (target INR 2.0-3.0) . In this trial, apixaban was superior to warfarin for the prevent ion of stroke or sys temic embolism , th e pr imar y efficacy end point. There also appeared to be a mort ality ben efit with ap ixaban versus warfarin . Imp ortantly, the risk of major and intracranial bleeding, the prim ary sa fety outcomes , occurred at lower rates in the apixaban group.
All three of these oral anticoagulants require dose adjustm ent in patien ts with renal insufficiency and are contraindic ated in patien ts with end-stage renal failure. They are not indicated in patients with valvular heart disease or a mech anical heart valves.
NONPHARMACOLOGIC INTERVENTIONS
Most atrial thrombi in pa tien ts with nonvalvular AF form in the LAA. Nonpharmaco logic int erventi ons have been developed to block the LAA to redu ce the risk of stroke. These are especially valuable options for patien ts who are not candidates for chro nic anticoagulation. In patients undergoing mitral valve surgery;" ligation to close the LAA has becom e a standard pra cti ce at experience d cente rs. The introdu ction of less invasive cathe ter-based interventions to occlude the LAA has provided add itional options.
Watchman device
Th e Watchman implant , a closure device that blocks the LAA, was recentl y approved by the US Foo d and Dru g Adminis tration (FDA) for stroke prevention in pati ents with non valvular AF wh o are at increased risk for stroke based on a CHA 2 DS 2 -VASc sco re of 2 or grea ter; candidat es also mu st have an appropriate rati on ale for nonph armacologic th erapy. T he expandable-cage device is surg ically delivered int o the LAA (Figu re 1) , which subseque ntly endo thelializes and isolates the LAA. Therapeutic warfarin is required for a minimum of 45 days after implan t followed by aspirin and clopid ogrel for 6 months and then aspirin alone .
This device was initially test ed in the PROTECT AF (Wa tch man Left Atrial Appendage Syst em for Embo lic PROTECTion in Patients with Atri al Fibrilla tion) trial , a noninferiority trial that randomized pati ents to eithe r device implant or warfarin. " Device implant was success fu l in 9 1% of patients in wh om it was attempted . Overall, th e study showed noninfer ior ity of th e dev ice to warfarin in terms of the primary efficacy standpoi nt, whi ch included stro ke, sys temic embolism, and cardiovasc ula r death ; h owever , this came at th e ex pe ns e o f high er in cid en ce o f procedure-relat ed co m plica tio ns, w h ic h seemed to b e d ep endent on a learn in g curve wit h th e device.
In the PREVA IL (Evaluatio n of the Wa tchma n LAA Closure Device in Patients with Atrial Fibrillation Versus Lon g-Term Warfarin Th erapy) trial," althoug h noninferiority was not achieved, the event rates were low and the safety of the procedure was mu ch imp roved. This was also d em on strated in registry data, wh ich showed improved safety with device implantation with increased operator experience.
or not e, both of the se trials included only pati ents who were eligible for warfarin. Another nonrandornized study" assessed the use of this device in pati en ts with a cont rai ndicatio n to lon g-term anticoagulation. Results showe d a very low incidence of stroke, which was lower than CHADS 2 -matched con trols taking either aspirin or clopidogrel. The FDA has approved this device for stroke preven tion in AF
Lariat system
The Lariat system is another percut aneous system for occlus io n of th e LAA. Th is device , which requires both atrial transseptal and epicardial access , ligates the app endage from the pericardial space . W h ile so me sma ll studies have shown it safe and efficacious in patients with AF wh o canno t tak e an ticoagulation ," other reports have not been as enco uraging." The device has been approved by the FDA for "soft tissue approxima tion"; it is not approved for stroke preventi on . 
SUMMARY
The most common serio us complications of AF are stroke and th romb oembolism. Medical and in terve ntional th erapies have been develop ed to prevent th ese co mplications. In patients with an estimated thromboembolic risk of greater than 1% to 2% per year, ant icoagulation is warrant ed to reduce th at risk. War farin rem ains one of the most stud ied and useful me dications for thi s purpose, but its use is limited by the need for frequent monitorin g, multiple dru g int eractions, dietary restri ctions, and, most imp ort antly, by the difficulty of co nsistent ly maintaining therapeuti c INRs.
Th e recently introduced novel ora l an ticoagu la n ts h ave been found to be a t least n oninferior to wa rfarin an d for so me agents to be su perior to warfarin for the pre vent io n of s tro ke and thromboemboli sm. The ir DECEMBER2015 • VOLUME 82 • SUPPLEMENT 2 • CLEVELAND CLI NIC JOURNAL OF MEDICINE • 815 main ad vantage is th at th ey do not require monitoring and have few er drug intera ctions and dietary restrictions. Mo st important, th ere appear to be fewer major and life-threatening bleeding events than with warfarin . How ever, us e of th ese nov el agents could be limited by patients' ren al fun ction, which needs to be assessed wh en th ese agents are being cons idered. Another limitation with th ese agents (vers us warfarin) is that patients are not th erapeutically anticoagulated when the y miss a do se , wh erea s missing a single dose of warfarin ma y not have th e same effect.
In our practice , we have transitioned to use of these novel oral anticoagulants whenever possible using an approach that assesses th e individual patient's risks for both s troke and thromboembolism as well as the risk for bl eeding. In pati ents who ar e at increased risk of bleeding but at risk of stro ke in AF, percutaneous occlusion of the LAA using the Wat chman device is offered. This device has been shown to be noninferior to warfarin for stro ke pr evention and ma y provide a survival ben efit due to th e reduction of life-threatening bleeding , which is an inherent risk with anticoagulants. One caveat is that th ere is a residual risk of stroke after undergoing LAA occlusion because the same risk factors for stroke in AF contribute to stroke from atherothrombosis anel atheroembolism ; also, thrombi can form in the body of the left atrium.
Clinical de cision-making is often challenging in patients with AF who are at risk of stroke and bleeding. In fact, these risk factors often overlap. In our practice, we have established a multidisciplinary clinic for stroke prevention in AF that involves cardiologists , cardiac electrophysiologists, neurologists, gastroenterologists , and vascular medicine spe cialis ts . This model allows a multidisciplinary assessment of patients' individual risks and ultimatel y facilitates clinical decision-making in terms of strategies to prevent stroke and thromboembolism in AF. 
